AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 APR 9 - (NewsRx.com & NewsRx.net) -- Acambis, plc, (ACAM) announced that it has completed a phase I trial of its smallpox vaccine, ACAM2000.
The trial assessed the safety, tolerability, and immunogenicity of ACAM2000 in adult subjects who had not previously been inoculated against smallpox. All 100 subjects in the open-label trial were vaccinated with ACAM2000.
The currently accepted indication of protective immunogenicity in the case of smallpox vaccination is the development of a pock-mark on the skin, known as a "take." This "take" was the primary endpoint of the trial and was seen in 99% of the ...